Tag: CBD-
Prenatal Cannabis Use Disorder Increases Risk for Neurodevelopmental Disorders
Risk increased for attention-deficit/hyperactivity disorder, autism spectrum disorder, and intellectual disability
2020 to 2022 Saw Increase in Enrollment in Medical Cannabis Programs
Proportion of patient-reported qualifying conditions with substantial, conclusive evidence of therapeutic value decreased
Considerable Prevalence of Δ8-THC Use Observed Among U.S. Teens
Prevalence was lower in Western versus Southern census regions, in states with regulations, in states with legal adult-use marijuana
Cannabis Use Linked to Adverse Cardiovascular Outcomes
Proportionately lower log odds seen for heart disease, MI, stroke, composite outcome for days of use between zero and 30 a month
Treatment for Cannabis Use Disorder Has Decreased Since 2004
For people with CUD in 2004 to 2014, specialty treatment decreased in states with medical cannabis laws with dispensary provisions
ED Visits for Cannabis Use Tied to Increased Risk for Incident Anxiety Disorder
Findings show threefold higher risk compared with the general population and even higher risk among young men
Asthma More Common Among Youth Reporting Cannabis Use
Findings suggest a dose-response relationship
Recent Cannabis Use Tied to Higher Risk of Current Asthma
Findings show dose-response relationship among U.S. individuals 12 years and older
Cannabis Does Not Impact Nonmedical Opioid Use in Opioid Use Disorder
No association seen between cannabis use and nonmedical opioid use in those receiving pharmacotherapies for OUD
FDA Says Marijuana Should Be Reclassified as Less Risky Drug
Currently, cannabis is classified as a Schedule I controlled substance, a category that includes heroin and LSD
